EQL's key product Memprex[©] has now been licensed for sale in BeNeLux (Belgium, Netherlands, Luxemburg) with Goodlife Specialty BV, a leading local pharmaceutical company specialising in women’s h...
EQL's key product methenamine hippurate has now gained marketing approval by the Health Authorities in France, where it is to be provided to patients by EQL's license partner Laboratoires Majorelle...
Sales and operating profit growth, significant product acquisition completed, 11 new products, first deal outside Europe and graduation year passed
EQL Pharma AB (publ) will publish its year-end report for the fourth quarter, 2024/25, on Thursday, May 8[th], before stock markets open.
EQL has entered into an exclusive distribution agreement with Pharmalink for its product Mellozzan (melatonin) for the GCC (Gulf Cooperation Council) region comprising of United Arab Emirates, Saud...
